1型糖尿病儿童接种PPSV23疫苗后的血清转换
这项前瞻性先导研究纳入29名未接种过PPSV23的1型糖尿病儿童,在免疫前和免疫后4-6周检测血清型特异性IgG。完成研究的25名儿童中88%(22/25)总体应答适当,中位变化4.2倍;年龄增长与应答增强显著相关(每年0.16 log2倍变化,95%CI 0.014至0.3,p=0.033)。
要点
- 完成研究的25名1型糖尿病儿童中88%(22/25)对PPSV23总体应答适当,中位变化4.2倍。
- 年龄增长与PPSV23独有血清型应答增强显著相关(每年0.16 log2倍变化,95%CI 0.014至0.3,p=0.033)。
- 较高年龄别BMI(p=0.085)和免疫后CGM血糖变异系数较低(p=0.067)也与应答增强一致,部分血清型达统计学显著。
核心结论
- 1型糖尿病儿童对PPSV23疫苗接种表现出稳健的体液免疫应答,但需更大规模、更多样化代表性和更长随访的研究来评估血清转换与临床应答的相关性。
研究设计与样本
- 前瞻性先导研究,招募29名未接种过PPSV23的1型糖尿病儿童,在基线及免疫后4-6周检测血清型特异性IgG。
主要发现
- 完成研究的25名儿童中88%(22/25)总体应答适当,免疫后中位变化4.2倍。
- PPSV23独有血清型中,年龄增长与应答增强显著相关(每年0.16 log2倍变化,95%CI 0.014至0.3,p=0.033)。
- 较高年龄别BMI(p=0.085)和免疫后CGM血糖变异系数较低(p=0.067)也与应答增强一致,部分肺炎球菌血清型两者均达统计学显著。
局限性
- 本研究为先导研究,样本量有限。
- 作者指出需要更大规模、更多样化代表性和更长随访的研究来评估体液血清转换与PPSV23临床应答的相关性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate whether children with type 1 diabetes mellitus (T1DM) have optimal humoral immune response to pneumococcal polysaccharide vaccination (PPSV23) and to study factors affecting that response. METHODS: In this prospective pilot study, we recruited 29 children with T1DM who were vaccine naïve to PPSV23 and assessed serum-serotype specific IgG at baseline and 4-6 weeks post-immunization. We tested association between independent variables (age, gender, body mass index (BMI), hemoglobin A1c (HbA1c), glucose variability, and time in range assessed by continuous glucose monitors (CGM), insulin dose and outcome (log-2-fold change of immunoassay response between pre- and post-immunization testing) using linear regression. RESULTS: Eighty-eight percent of children (22/25) who completed the study had overall appropriate response with a median 4.2-fold change following immunization. When assessing PPSV23-exclusive serotypes, there was a statistically significant correlation between increasing age and greater response (0.16 log2-fold change per year, 95 % CI (0.014 to 0.3), p = 0.033). Higher BMI for age (p = 0.085) and a lower coefficient of glucose variation from CGM following immunization (p = 0.067) also coincided with greater vaccine response, with correlation statistically significant for certain pneumococcal serotypes for both. CONCLUSIONS: Response to pneumococcal vaccination has not previously been assessed in children with T1DM, and our study demonstrates robust humoral immune response to PPSV23 vaccination in these children. Larger studies with a diverse representation and longer follow up to assess how humoral seroconversion correlates with clinical response to PPSV23 in this vulnerable population are warranted.
引用
- Ender E, Joshi A, Snyder M, et al. Seroconversion following PPSV23 vaccination in children with type 1 diabetes mellitus. Vaccine. 2024. PMID: 39667114. doi:10.1016/j.vaccine.2024.126592
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。